218 related articles for article (PubMed ID: 7929843)
21. Variable gene expression within human tyrosinemia type 1 liver may reflect region-specific dysplasia.
Haber BA; Chuang E; Lee W; Taub R
Hepatology; 1996 Jul; 24(1):65-71. PubMed ID: 8707285
[TBL] [Abstract][Full Text] [Related]
22. The human fumarylacetoacetase gene: characterisation of restriction fragment length polymorphisms and identification of haplotypes in tyrosinemia type 1 and pseudodeficiency.
Rootwelt H; Kvittingen EA; Høie K; Agsteribbe E; Hartog M; van Faassen H; Berger R
Hum Genet; 1992 May; 89(2):229-33. PubMed ID: 1350265
[TBL] [Abstract][Full Text] [Related]
23. Identification of a combined missense/splice-site mutation in FAH causing tyrosinemia type 1.
Haghighi-Kakhki H; Rezazadeh J; Ahmadi-Shadmehri A
J Pediatr Endocrinol Metab; 2014 Jul; 27(7-8):795-8. PubMed ID: 24756054
[TBL] [Abstract][Full Text] [Related]
24. Type I tyrosinemia: lack of immunologically detectable fumarylacetoacetase enzyme protein in tissues and cell extracts.
Berger R; Van Faassen H; Taanman JW; De Vries H; Agsteribbe E
Pediatr Res; 1987 Oct; 22(4):394-8. PubMed ID: 3317254
[TBL] [Abstract][Full Text] [Related]
25. Tyrosine and its catabolites: from disease to cancer.
Tanguay RM; Jorquera R; Poudrier J; St-Louis M
Acta Biochim Pol; 1996; 43(1):209-16. PubMed ID: 8790725
[TBL] [Abstract][Full Text] [Related]
26. Deficiency of fumarylacetoacetase without hereditary tyrosinemia.
Kvittingen EA; Børresen AL; Stokke O; van der Hagen CB; Lie SO
Clin Genet; 1985 Jun; 27(6):550-4. PubMed ID: 4017276
[TBL] [Abstract][Full Text] [Related]
27. Deficient fumarylacetoacetate fumarylhydrolase activity in lymphocytes and fibroblasts from patients with hereditary tyrosinemia.
Kvittingen EA; Halvorsen S; Jellum E
Pediatr Res; 1983 Jul; 17(7):541-4. PubMed ID: 6622096
[TBL] [Abstract][Full Text] [Related]
28. Mutations in the 4-hydroxyphenylpyruvic acid dioxygenase gene are responsible for tyrosinemia type III and hawkinsinuria.
Tomoeda K; Awata H; Matsuura T; Matsuda I; Ploechl E; Milovac T; Boneh A; Scott CR; Danks DM; Endo F
Mol Genet Metab; 2000 Nov; 71(3):506-10. PubMed ID: 11073718
[TBL] [Abstract][Full Text] [Related]
29. Tyrosinemia type 1--complex splicing defects and a missense mutation in the fumarylacetoacetase gene.
Rootwelt H; Kristensen T; Berger R; Høie K; Kvittingen EA
Hum Genet; 1994 Sep; 94(3):235-9. PubMed ID: 8076937
[TBL] [Abstract][Full Text] [Related]
30. Splicing mutations, mainly IVS6-1(G>T), account for 70% of fumarylacetoacetate hydrolase (FAH) gene alterations, including 7 novel mutations, in a survey of 29 tyrosinemia type I patients.
Arranz JA; Piñol F; Kozak L; Pérez-Cerdá C; Cormand B; Ugarte M; Riudor E
Hum Mutat; 2002 Sep; 20(3):180-8. PubMed ID: 12203990
[TBL] [Abstract][Full Text] [Related]
31. A novel mutation causing mild, atypical fumarylacetoacetase deficiency (Tyrosinemia type I): a case report.
Cassiman D; Zeevaert R; Holme E; Kvittingen EA; Jaeken J
Orphanet J Rare Dis; 2009 Dec; 4():28. PubMed ID: 20003495
[TBL] [Abstract][Full Text] [Related]
32. Gene structure, chromosomal location, and expression pattern of maleylacetoacetate isomerase.
Fernández-Cañón JM; Hejna J; Reifsteck C; Olson S; Grompe M
Genomics; 1999 Jun; 58(3):263-9. PubMed ID: 10373324
[TBL] [Abstract][Full Text] [Related]
33. [Tyrosinemia].
Salo MK
Duodecim; 1992; 108(9):841-3. PubMed ID: 1366298
[No Abstract] [Full Text] [Related]
34. Fumarylacetoacetase mutations in tyrosinaemia type I.
Rootwelt H; Høie K; Berger R; Kvittingen EA
Hum Mutat; 1996; 7(3):239-43. PubMed ID: 8829657
[TBL] [Abstract][Full Text] [Related]
35. Enzyme defect in a case of tyrosinemia type I, acute form.
Furukawa N; Kinugasa A; Seo T; Ishii T; Ota T; Machida Y; Inoue F; Imashuku S; Kusunoki T; Takamatsu T
Pediatr Res; 1984 May; 18(5):463-6. PubMed ID: 6145143
[TBL] [Abstract][Full Text] [Related]
36. Two novel mutations involved in hereditary tyrosinemia type I.
St-Louis M; Poudrier J; Phaneuf D; Leclerc B; Laframboise R; Tanguay RM
Hum Mol Genet; 1995 Feb; 4(2):319-20. PubMed ID: 7757089
[No Abstract] [Full Text] [Related]
37. Identification of a frequent pseudodeficiency mutation in the fumarylacetoacetase gene, with implications for diagnosis of tyrosinemia type I.
Rootwelt H; Brodtkorb E; Kvittingen EA
Am J Hum Genet; 1994 Dec; 55(6):1122-7. PubMed ID: 7977370
[TBL] [Abstract][Full Text] [Related]
38. Ex vivo hepatic gene therapy of a mouse model of Hereditary Tyrosinemia Type I.
Overturf K; Al-Dhalimy M; Manning K; Ou CN; Finegold M; Grompe M
Hum Gene Ther; 1998 Feb; 9(3):295-304. PubMed ID: 9508047
[TBL] [Abstract][Full Text] [Related]
39. Hereditary tyrosinemia type 1: novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene; variability of the genotype-phenotype relationship.
Ploos van Amstel JK; Bergman AJ; van Beurden EA; Roijers JF; Peelen T; van den Berg IE; Poll-The BT; Kvittingen EA; Berger R
Hum Genet; 1996 Jan; 97(1):51-9. PubMed ID: 8557261
[TBL] [Abstract][Full Text] [Related]
40. Molecular and functional analysis of SLC25A20 mutations causing carnitine-acylcarnitine translocase deficiency.
Iacobazzi V; Invernizzi F; Baratta S; Pons R; Chung W; Garavaglia B; Dionisi-Vici C; Ribes A; Parini R; Huertas MD; Roldan S; Lauria G; Palmieri F; Taroni F
Hum Mutat; 2004 Oct; 24(4):312-20. PubMed ID: 15365988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
